Ronald I. Meltzer
Directeur/Membre du Conseil chez Sequella, Inc.
Profil
Ronald I.
Meltzer is currently a Director at Sequella, Inc. and a Member-Washington Leadership Board at State University of New York at Buffalo Law School.
He formerly worked as a Principal at American University and as a Professor at State University of New York at Buffalo.
He holds a doctorate degree from The Trustees of Columbia University in The City of New York, a graduate degree from New York University, and an undergraduate degree from The Ohio University.
Postes actifs de Ronald I. Meltzer
Sociétés | Poste | Début |
---|---|---|
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | Directeur/Membre du Conseil | - |
State University of New York at Buffalo Law School | Corporate Officer/Principal | 20/07/2011 |
Anciens postes connus de Ronald I. Meltzer
Sociétés | Poste | Fin |
---|---|---|
American University | Corporate Officer/Principal | - |
State University of New York at Buffalo | Corporate Officer/Principal | - |
Formation de Ronald I. Meltzer
New York University | Graduate Degree |
The Trustees of Columbia University in The City of New York | Doctorate Degree |
The Ohio University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | Health Technology |